- Home
- HUMA vs HELP Comparison
HUMA vs HELP Comparison
Compare HUMA & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUMA | HELP |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | Canada |
| Employees | 184 | 50 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.6M | 279.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HUMA | HELP |
|---|---|---|
| Price | $1.35 | $4.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $6.19 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 7.8M | 602.8K |
| Earning Date | 05-15-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $444.16 | N/A |
| Revenue Next Year | $248.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $4.15 |
| 52 Week High | $2.84 | $8.55 |
Technical Indicators
Market Signals| Indicator | HUMA | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 37.36 |
| Support Level | $0.89 | N/A |
| Resistance Level | $1.72 | $6.26 |
| Average True Range (ATR) | 0.13 | 0.27 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 75.52 | 10.27 |
Price Performance
Historical ComparisonAbout HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.